emerg
new
pathogen
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
viru
pose
seriou
challeng
global
public
health
highlight
urgent
need
novel
antivir
approach
monoclon
antibodi
mab
success
use
treat
variou
diseas
particularli
cancer
immunolog
disord
antigenspecif
mab
isol
use
sever
differ
approach
includ
hybridoma
transgen
mice
phage
display
yeast
display
singl
bcell
isol
consequ
increas
number
mab
exhibit
high
potenc
emerg
virus
vitro
anim
model
infect
develop
paper
summar
histor
trend
recent
develop
mab
discoveri
compar
advantag
disadvantag
variou
approach
mab
product
discuss
potenti
use
strategi
develop
antivir
emerg
diseas
also
review
applic
recent
develop
human
mab
sarscov
merscov
ebola
viru
discuss
prospect
develop
mab
therapeut
agent
emerg
viral
diseas
emerg
infecti
diseas
infecti
diseas
caus
previous
unknown
unnot
pathogen
microorgan
pathogen
mostli
virus
could
newli
discov
previous
known
control
recent
reemerg
rapidli
increas
incid
andor
geograph
rang
outbreak
emerg
infecti
diseas
pose
seriou
challeng
global
public
health
three
recent
exampl
illustr
challeng
present
emerg
infecti
diseas
first
sever
acut
respiratori
syndrom
sar
emerg
pandem
caus
sever
acut
respiratori
syndrom
coronaviru
sarscov
previous
unknown
viru
viru
first
isol
specimen
three
patient
sar
accord
world
health
organ
sar
infect
peopl
caus
least
death
specif
therapeut
agent
effect
vaccin
sar
unavail
time
initi
outbreak
fortun
sar
success
contain
addit
sar
outbreak
report
sinc
second
exampl
come
ebola
viru
outbreak
although
first
recogn
outbreak
ebola
viru
occur
novel
variant
ebola
viru
emerg
west
african
nation
march
estim
march
case
death
occur
recent
outbreak
third
exampl
middl
east
respiratori
syndrom
mer
caus
middl
east
respiratori
syndrom
coronaviru
merscov
novel
coronaviru
decad
sar
epidem
mer
first
appear
saudi
arabia
soon
spread
countri
includ
unit
arab
emir
qatar
oman
jordan
kuwait
yemen
lebanon
mer
led
infect
individu
fatal
rate
http
three
recent
outbreak
clearli
show
emerg
diseas
pose
consider
threat
public
health
effect
treatment
need
develop
face
tremend
challeng
pose
emerg
infecti
diseas
monoclon
antibodi
mab
base
therapi
recent
use
treatment
variou
infect
exampl
mab
treatment
correl
increas
antibodi
level
decreas
ebola
viral
load
without
observ
advers
effect
review
focus
applic
mab
therapeut
agent
emerg
virus
exemplifi
sarscov
merscov
ebola
viru
begin
brief
histor
remark
highlight
import
characterist
three
emerg
virus
candid
mabbas
therapi
histor
perspect
antibodybas
serum
therapi
mab
therapi
activ
vaccin
stimul
product
antitoxin
antibodi
serum
emil
von
behr
paul
ehrlich
first
use
serum
immun
hors
treat
diphtheria
serum
contain
small
amount
neutral
antibodi
could
neutral
toxin
associ
pathogenesi
diphtheria
serum
therapi
thu
provid
new
treatment
option
sever
bacteri
infect
antibodi
immunoglobulin
g
igg
class
typic
prefer
therapeut
antibodi
igg
one
abund
protein
human
serum
igg
neutral
effect
activ
complement
system
effector
cell
kill
pathogen
infect
cell
trigger
phagocyt
cell
initi
success
serum
therapi
extens
use
prophylaxi
therapi
viral
bacteri
diseas
although
effect
sever
diseas
numer
side
effect
thu
almost
abandon
discoveri
antibiot
moreov
antibiot
therapi
desir
serum
therapi
treatment
bacteri
infect
given
lower
product
cost
toxic
fewer
side
effect
howev
antibiot
ineffect
viral
infect
addit
extens
use
antibiot
led
develop
multidrugresist
bacteria
therefor
despit
toxicityrel
problem
includ
risk
allerg
reaction
lottolot
variat
uncertain
dose
antibodybas
serum
therapi
still
use
prevent
treatment
sever
viral
diseas
includ
cytomegalovir
infect
hepat
hepat
b
rabi
measl
fundament
limit
serum
therapi
attribut
polyclon
natur
antibodi
function
antibodi
polyclon
prepar
typic
account
small
portion
total
antibodi
remain
antibodi
ineffect
may
even
toxic
immunogen
therefor
clinic
applic
antibodi
remain
limit
antibodybas
therapi
rejuven
discoveri
technolog
mab
product
kohler
et
al
gener
mous
hybridoma
cell
fusion
mous
myeloma
cell
mous
spleen
cell
immun
sheep
red
blood
cell
hybridoma
cell
could
specif
produc
antisheep
erythrocyt
antibodi
develop
hybridoma
technolog
allow
product
mab
homogen
antibodi
specif
singl
ig
class
isotyp
mab
quickli
appli
clinic
set
howev
applic
mab
human
led
human
antimous
antibodi
respons
hama
reaction
strategi
attenu
avoid
hama
reaction
either
human
mous
mab
develop
fulli
human
mab
hmab
develop
hmab
mab
use
treatment
variou
diseas
includ
cancer
autoimmun
diseas
infecti
diseas
although
humanmous
chimer
mab
replac
mous
igg
fc
human
human
mab
replac
human
complementaritydetermin
region
mice
effect
clinic
set
still
contain
portion
mous
origin
induc
immunogen
hama
reaction
smith
et
al
develop
phage
display
techniqu
techniqu
mainli
character
express
specif
protein
phage
surfac
integr
protein
gene
phage
dna
process
led
gener
phagedisplay
antibodi
librari
random
pair
antibodi
heavi
light
chain
enabl
use
appropri
target
antigen
screen
specif
antibodi
high
affin
antigen
fig
phage
display
technolog
extens
use
gener
fulli
human
antibodi
librari
consequ
provid
rapid
highli
effect
approach
obtain
specif
antibodi
infecti
diseas
human
transgen
mice
also
provid
valuabl
platform
gener
fulli
human
therapeut
antibodi
human
transgen
mice
endogen
mous
antibodi
gene
replac
human
ig
loci
transgen
mice
immun
target
antigen
ensur
express
specif
human
antibodi
target
antigen
kymab
velocimmun
mice
repres
transgen
mous
model
produc
high
yield
highaffin
human
antibodi
howev
effect
differ
mous
human
immun
system
especi
antibodi
affin
matur
pathway
clinic
outcom
remain
unknown
sever
methodolog
includ
yeast
display
singl
b
cell
isol
recent
use
success
identifi
candid
therapeut
antibodi
principl
yeast
display
similar
phage
display
common
yeast
surfac
display
system
involv
connect
display
antibodi
fragment
c
terminu
subunit
link
subunit
two
disulfid
bond
yeast
display
system
ideal
antibodi
affin
matur
due
effect
flow
cytometri
discrimin
strong
weak
affin
binder
initi
step
singl
bcell
isol
select
antigenposit
b
cell
fluorescenceactiv
cell
sort
antigenco
magnet
bead
system
microengrav
cellbas
microarray
chip
system
b
cell
could
immort
epsteinbarr
viru
ebv
transform
heavyand
lightchain
sequenc
obtain
revers
transcriptionpolymeras
chain
reaction
rtpcr
although
singl
bcell
isol
use
effici
isol
potent
neutral
antibodi
timeconsum
requir
fig
workflow
mab
discoveri
use
phage
display
librari
first
human
heavi
light
chain
gene
obtain
b
cell
donor
insert
phagemid
vector
antibodi
fab
singlechain
variabl
region
fragment
scfv
format
display
surfac
phage
target
antigen
coupl
magnet
bead
coat
plate
cyclic
pan
select
phage
desir
target
specif
affin
enrich
binder
select
subsequ
clone
express
character
virul
five
ebola
virus
vari
zebov
highest
mortal
rate
genom
ebola
viru
encod
seven
structur
multifunct
protein
envelop
glycoprotein
gp
nucleoprotein
np
rna
polymeras
l
viral
protein
gp
embed
virion
surfac
type
transmembran
glycoprotein
encod
amino
acid
transcript
modif
gp
consist
solubl
gp
small
solubl
gp
gp
function
close
associ
receptor
bind
viral
entri
coagul
abnorm
patient
infect
ebola
viru
addit
gpmediat
cytotox
associ
pathogenesi
differ
ebola
subtyp
gp
thu
ideal
target
antiebola
drug
furthermor
theoret
analysi
reveal
antigen
epitop
gp
largest
epitop
ebola
viru
vaccin
test
base
gp
np
show
gp
good
immunogen
effect
word
gp
alon
enough
induc
product
protect
antibodi
fatal
ebola
viru
attack
meanwhil
immun
np
alon
exert
protect
effect
suggest
gp
ideal
target
develop
neutral
antibodi
ebola
develop
mab
therapi
evd
urgent
need
prevent
evd
outbreak
highaffin
neutral
mab
specif
target
main
gp
epitop
ebola
viru
identifi
antibodi
obtain
phage
display
librari
gener
use
rna
donor
recov
ebola
infect
could
neutral
ebola
viru
nmoll
could
also
protect
guinea
pig
lethal
zebov
challeng
howev
antibodi
fail
provid
protect
test
rhesu
macaqu
model
better
understand
mechan
underli
neutral
effect
antiebola
mab
research
analyz
panel
mab
react
gp
found
two
neutral
mab
neutral
ebola
viru
two
fundament
differ
mechan
specif
inhibit
cathepsin
cleavag
gp
wherea
recogn
postcleavag
gp
result
suggest
multipl
epitop
need
target
success
ebola
treatment
promis
approach
develop
multimab
cocktail
ebola
viru
zmab
repres
cocktail
antibodi
ebola
viru
zmab
cocktail
antibodi
develop
mapp
biopharmaceuti
consist
three
monoclon
neutral
antibodi
also
compos
three
mab
name
develop
canadian
public
health
agenc
two
cocktail
antibodi
isol
mice
immun
zebov
gp
protein
trimer
cynomolgu
macaqu
infect
model
treatment
initi
h
post
challeng
zmab
exhibit
protect
rate
show
protect
rate
howev
viru
escap
one
ebola
virusinfect
anim
treat
result
five
nonsynonym
mutant
antibodytarget
site
mutant
decreas
antibodi
bind
vitro
find
highlight
import
select
differ
target
site
antibodi
cocktail
minim
potenti
viral
escap
combin
novel
cocktail
antibodi
call
zmapp
contrast
zmab
zmapp
contain
antibodi
zmapp
exhibit
potent
neutral
activ
ebola
viru
rhesu
macaqu
primat
infect
model
show
protect
effect
zmapp
stronger
zmab
eighteen
ebola
viru
challeng
macaqu
receiv
intraven
inject
zmapp
day
postinfect
mgkg
per
dose
compar
previou
evd
treatment
method
time
inject
sever
day
later
model
rhesu
macaqu
cure
treatment
two
american
patient
dr
kent
brantli
nanci
writebol
infect
ebola
viru
work
west
africa
return
unit
state
treatment
treat
zmapp
repres
first
time
zmapp
use
human
physic
condit
two
patient
improv
treatment
zmapp
find
suggest
emerg
case
antibodi
effect
sever
anim
model
could
use
save
human
live
howev
case
whether
antibodi
immun
system
respons
recoveri
remain
unclear
recent
anoth
neutral
antibodi
ebola
viru
isol
blood
two
survivor
evd
outbreak
kikwit
antibodi
could
protect
macaqu
five
day
infect
ebola
viru
structur
analysi
reveal
mediat
viru
neutral
inhibit
bind
proteasecleav
gp
receptor
addit
heterolog
animalderiv
polyclon
antibodi
exert
neutral
effect
ebola
viru
surviv
achiev
anim
studi
ebola
viru
polyclon
antibodi
deliv
h
viral
challeng
novemb
sar
outbreak
initi
sarscov
first
occur
guangdong
provinc
china
sarscov
highli
contagi
caus
sever
clinic
symptom
could
result
death
accord
sarscov
spread
countri
region
led
infect
peopl
death
peopl
mortal
rate
close
sarscov
belong
coronaviru
famili
coronaviru
genu
genom
approxim
kb
length
given
nucleotid
composit
sarscov
genom
drastic
differ
known
coronaviru
sequenc
could
attribut
known
group
exist
coronavirus
time
initi
outbreak
sarscov
genom
encod
protein
previou
studi
coronavirus
shown
envelop
protein
strong
immunogen
effect
sarscov
bind
receptor
angiotensin
convert
enzym
receptorbind
domain
rbd
envelop
glycoprotein
earli
work
show
hmab
exhibit
inhibitori
effect
sarscov
thu
develop
potent
inhibitori
mab
sarscov
high
prioriti
sever
group
success
develop
hmab
sarscov
identifi
two
nonimmun
human
antibodi
librari
recombin
human
scfv
domain
spike
protein
sarscov
potent
neutral
effect
sarscov
strongli
inhibit
syncytia
format
cell
express
protein
express
anoth
studi
ebv
use
immort
memori
b
cell
patient
recov
sarscov
infect
strategi
mab
isol
exhibit
high
viral
neutral
activ
sarscov
sarscov
infect
mous
model
transfer
mice
intraperiton
rout
two
day
mice
receiv
intranas
challeng
dose
sarscov
inject
protect
mice
recurr
viral
challeng
howev
unabl
neutral
strain
sarscov
isol
index
patient
second
sarscov
outbreak
therefor
group
express
fragment
contain
residu
sarscov
rbd
insect
cell
use
select
antigen
identifi
larg
human
antibodi
fab
librari
construct
b
lymphocyt
healthi
volunt
found
achiev
inhibit
differ
sarscov
subtyp
low
concentr
inject
complet
protect
mous
model
sarscov
sarscov
infect
thu
potenti
use
alon
combin
develop
potent
antibodybas
therapeut
sarscov
septemb
erasmu
medic
center
isol
new
patient
rotterdam
citi
isol
later
name
merscov
intern
commiss
classif
coronaviru
studi
group
symptom
patient
merscov
similar
patient
sarscov
mainli
includ
fever
cough
short
breath
patient
sever
merscov
infect
experienc
renal
failur
lethal
rate
merscov
approxim
consider
higher
sarscov
septemb
laboratoryconfirm
case
merscov
infect
includ
least
relat
death
report
http
merscov
belong
lineag
c
merscov
genom
encod
highli
conserv
polymeras
helicas
highli
differenti
spike
protein
five
helper
protein
highli
conserv
envelop
protein
e
membran
protein
nucleoprotein
n
protein
exist
trimer
viral
surfac
contain
two
function
subunit
name
subunit
respons
receptor
bind
proxim
membran
side
subunit
respons
mediat
membran
fusion
merscov
interact
receptor
dipeptidyl
also
known
rbd
protein
mediat
adsorpt
onto
cell
highli
conserv
mammal
mainli
express
lung
kidney
liver
small
intestin
pancrea
epitheli
cell
surfac
adsorpt
viru
fuse
cell
membran
enter
cell
initi
infect
sever
differ
group
develop
potent
neutral
antibodi
merscov
exampl
isol
dozen
antibodi
high
neutral
activ
merscov
fulli
human
antibodi
librari
establish
use
phage
display
among
antibodi
found
mab
strongest
neutral
activ
reach
pmoll
level
structur
fab
complex
merscov
rbd
suggest
epitop
almost
complet
overlap
natur
rbd
viral
surfac
except
one
amino
acid
mutat
heavi
chain
sever
light
chain
sequenc
antibodi
almost
nativ
germlin
predecessor
antibodi
use
develop
highli
effect
antimerscov
drug
given
germlin
antibodi
usual
low
immunogen
high
safeti
level
anoth
studi
jiang
et
al
describ
develop
potent
merscovneutr
mab
use
yeast
display
method
mab
rapidli
gener
use
cellclon
technolog
immort
b
cell
deriv
human
donor
recov
mer
subnanomolar
nmoll
affin
protein
merscov
pascal
et
al
also
gener
hmab
human
mice
use
velocimmun
technolog
mab
also
show
therapeut
efficaci
mous
model
merscov
infect
given
develop
field
inhibitori
mab
influenc
use
mab
develop
diagnost
therapeut
strategi
emerg
infecti
diseas
expect
expand
research
inhibitori
mab
flourish
given
rapid
develop
novel
technolog
product
antigenspecif
mab
increas
need
novel
mabbas
therapi
infecti
diseas
antivir
mab
gener
use
sever
differ
method
eg
phage
display
human
mous
vari
advantag
disadvantag
tabl
among
method
larg
antibodi
phage
librarybas
technolog
enabl
rapid
develop
highaffin
hmab
emerg
viral
diseas
occur
outbreak
set
lowcost
method
use
isol
candid
mab
within
sever
week
without
need
blood
infect
patient
elabor
screen
anim
feed
facil
numer
mab
inhibitori
effect
infecti
diseas
avail
promis
candid
therapeut
clinic
applic
howev
hinder
expens
associ
develop
product
african
countri
infecti
diseas
highli
preval
constitut
largest
market
mabbas
therapi
howev
mani
patient
countri
afford
mabbas
therapi
long
run
govern
subsid
treatment
cost
compani
academ
improv
technolog
decreas
cost
therapi
exampl
american
australian
govern
support
develop
potent
mab
hendra
viru
approv
human
use
success
test
two
anim
model
complet
human
phase
clinic
trial
volunt
anoth
promis
avenu
develop
small
antibodi
construct
singledomain
antibodi
significantli
cheaper
produc
convent
fullsiz
mab
current
therapeut
use
antibodi
construct
limit
unsatisfactorili
short
vivo
halfliv
disadvantag
may
overcom
antibodi
engin
technolog
eg
confer
neonat
fc
receptor
fcrn
bind
capabl
enabl
fcrnmediat
recycl
prevent
endosom
degrad
lowcost
longlast
novel
antibodi
construct
may
great
potenti
extens
applic
treatment
emerg
viral
diseas
